Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142620 | 0.99 | PHLPP2 (0.53) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL164701 | 0.99 | PHLPP2 (0.53) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL15226561 | 0.95 | PHLPP2 (0.50) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| Hydroxyamine SCHEMBL16653989 | 0.95 | PHLPP2 (0.50) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL164702 | 0.94 | PHLPP2 (0.57) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| Butane SCHEMBL10710653 | 0.93 | PHLPP2 (0.48) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL6703786 | 0.93 | HIF1A (0.52) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL29647872 | 0.93 | HIF1A (0.52) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL30959846 | 0.93 | HIF1A (0.52) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1181224 | 0.91 | PHLPP2 (0.55) | PHLPP2HIF1AKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880688-B1 | OLIGOSACCHARIDE PREPARATIONS AND COMPOSITIONS | DSM IP ASSETS BV (NL) | 2025-09-17 | — | — | EP | claimed |
| US-11820973-B2 | Methods and system for interfering with viability of bacteria and related compounds and compositions | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-11-21 | — | — | US | claimed |
| US-11655267-B2 | Oligosaccharide preparations and compositions | DSM IP ASSETS B.V. (NL) | 2023-05-23 | — | — | US | claimed |
| EP-4735009-A1 | FERRITIN-GOLD NANOPARTICLE CONJUGATES FOR PHOTODYNAMIC CANCER THERAPY | Temple University Of The Commonwealth System Of Higher Education (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4687916-A1 | OLIGOSACCHARIDE PREPARATION COUNTERACTING RESPIRATORY DISEASE EFFECT | DSM IP Assets B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-3880688-B1 | OLIGOSACCHARIDE PREPARATIONS AND COMPOSITIONS | DSM IP ASSETS BV (NL) | 2025-09-17 | — | — | EP | disclosed |
| EP-4613755-A1 | OLIGOSACCHARIDE PREPARATIONS AND COMPOSITIONS | DSM IP Assets B.V. (NL) | 2025-09-10 | — | — | EP | disclosed |
| US-20250212913-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-07-03 | — | — | US | disclosed |
| US-20250185693-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-20250185694-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-20250185695-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS BV (NL) | 2025-06-12 | — | — | US | disclosed |
| US-20230200412-A1 | METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES | DSM IP ASSETS B.V. (NL) | 2023-06-29 | — | — | US | disclosed |
| WO-2023110658-A1 | USE OF OLIGOSACCHARIDE PREPARATION TO INCREASE PERFORMANCE OF ANIMAL VACCINATED AGAINST COCCIDIOSIS | DSM IP ASSETS B.V. (NL) | 2023-06-22 | — | — | WO | disclosed |
| US-11655267-B2 | Oligosaccharide preparations and compositions | DSM IP ASSETS B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| EP-4162808-A1 | METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASIS | DSM IP Assets B.V. (NL) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023007003-A1 | SELF-ASSEMBLED BIOCOMPATIBLE IMAGING PARTICLES, THEIR SYNTHESIS AND THEIR USE IN IMAGING TECHNIQUES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-02-02 | — | — | WO | disclosed |
| EP-4118090-A1 | METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES | DSM IP Assets B.V. (NL) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022175267-A1 | METHODS FOR REDUCING PATHOGENIC E COLI BY SELECTIVE FEED ADDITIVE INTERVENTION | DSM IP ASSETS B.V. (NL) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022117739-A1 | OLIGOSACCHARIDE FORMULATION | DSM IP ASSETS B.V. (NL) | 2022-06-09 | — | — | WO | disclosed |
| US-20220125074-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2022-04-28 | — | — | US | disclosed |